` CYDY (Cytodyn Inc) vs S&P 500 Comparison - Alpha Spread

CYDY
vs
S&P 500

Over the past 12 months, CYDY has significantly outperformed S&P 500, delivering a return of +139% compared to the S&P 500's +14% growth.

Stocks Performance
CYDY vs S&P 500

Loading
CYDY
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CYDY vs S&P 500

Performance Gap Between CYDY and GSPC
HIDDEN
Show

Performance By Year
CYDY vs S&P 500

Loading
CYDY
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Cytodyn Inc vs Peers

S&P 500
CYDY
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Cytodyn Inc
Glance View

Market Cap
351.9m USD
Industry
Biotechnology

CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. The company is headquartered in Vancouver Washington, Washington and currently employs 24 full-time employees. The company went IPO on 2005-11-17. The CCR5 receptor is a protein located on the surface of various cells including white blood cells and cancer cells. The CCR5 receptor is also the co-receptor needed for certain strains of human immunodeficiency virus (HIV) to infect healthy T-cells. The firm also completed a Phase IIb/III investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients. The firm is also conducting a Phase II clinical trial with leronlimab in metastatic Triple Negative Breast Cancer (mTNBC), a Phase II basket trial in solid tumor cancers (22 different cancer indications), Phase II investigative trial for post-acute sequelae of SARS COV-2, also known as COVID-19 long haulers, and a Phase II clinical trial for nonalcoholic steatohepatitis (NASH).

CYDY Intrinsic Value
Not Available
Back to Top